Sitagliptin's renoprotective effect in a diabetic nephropathy model in rats: The potential role of PI3K/AKT pathway.

Abstract

Management of diabetic nephropathy (DN) is far from satisfactory. There is a rising role of the involvement of phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) pathway in the pathogenesis of DN. This study aimed at investigating the renoprotective effects of PI3K/AKT pathway via sitagliptin in a rat model of DN. Thirty-two male Wistar rats were divided into four groups (eight rats each): (I) control, (II) sitagliptin, (III) DN, and (IV) DN + sitagliptin. Fasting blood glucose (FBG), kidney index, and kidney function tests in both blood and urine were measured. The levels of superoxide dismutase (SOD), tumor necrosis factor-alpha (TNF-α), and transforming growth factor-beta (TGF-β) and gene expressions of PI3K, pPI3K, AKT, and pAKT in renal tissue were detected. Renal histopathological and immunohistochemical studies were evaluated. DN + sitagliptin group showed significant decrease in FBG and kidney index, improvement in kidney function tests, and a decrease in levels of TNF-α and TGF-β in renal tissues compared with DN group. This was associated with significant increase in SOD and gene expressions of PI3K and AKT and their phosphorylated active forms in renal tissue in DN + sitagliptin group compared with DN group. Moreover, DN + sitagliptin group showed apparent decrease in amount of collagen fibers and expression of alpha-smooth muscle actin (α-SMA) compared with DN group. This work shows that sitagliptin improved renal functions and histopathological changes, impeded inflammation, and oxidative stress and upregulated PI3K/AKT pathway which highlights its renoprotective effects in a rat model of DN.

• Authors: Reham Hussein Mohamed, Amina Ahmed Sedky, Ghada Galal Hamam, Lobna Elkhateb, Sherif A Kamar, Seham Adel, Sherin Shafik Tawfik
• Journal: Fundamental & clinical pharmacology (Fundam Clin Pharmacol) Vol. 36 Issue 2 Pg. 324-337 (Apr 2022) ISSN: 1472-8206 [Electronic] England
• PMID: 34735026 (Publication Type: Journal Article)
• Copyright: © 2021 Société Française de Pharmacologie et de Thérapeutique.

Chemical References

• Phosphatidylinositol 3-Kinase
• Proto-Oncogene Proteins c-akt
• Sitagliptin Phosphate

Topics

• Animals
• Diabetes Mellitus, Experimental (complications, drug therapy, metabolism)
• Diabetic Nephropathies (drug therapy, prevention & control)
• Kidney
• Male
• Phosphatidylinositol 3-Kinase (metabolism, pharmacology)
• Phosphatidylinositol 3-Kinases (metabolism)
• Proto-Oncogene Proteins c-akt (metabolism)
• Rats
• Rats, Wistar
• Sitagliptin Phosphate (metabolism, pharmacology)